$BTM

Bitcoin Depot Stock to Reverse Split on Monday, February 23rd (NASDAQ:BTM)

Bitcoin Depot (NASDAQ:BTM) announced a 1-for-7 reverse stock split effective Monday, February 23rd, with share adjustments occurring after the market close on Friday, February 20th. The company, which operates a large network of cryptocurrency kiosks, has a market capitalization of $69.22 million and a P/E of 4.13. Analysts currently have a "Hold" consensus rating on the stock with a target price of $5.83, despite recent downgrades from some firms.

Original reporting
MarketBeat · MarketBeat
Published Feb 20, 2026, 12:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 20, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bitcoin Depot Stock to Reverse Split on Monday, February 23rd (NASDAQ:BTM) — source image
Decision brief

The 30-second read

$BTMNeutralMed
01

Why it matters

The reverse split aims to meet NASDAQ listing requirements and potentially attract institutional investors. However, it does not address underlying financial challenges.

02

Market read

The event is primarily relevant to current shareholders and short-term traders; it has limited broader market implications.

03

What to watch

Potential for improved liquidity and perception if the company successfully executes its strategic plans post-split; also, broader market conditions could influence stock performance.

Relevance 6/10Timing: Immediate, as the reverse split occurs on February 23, 2026.

Background

Bitcoin Depot operates a large network of cryptocurrency kiosks and has a market cap of approximately $69.22 million, with a P/E ratio of 4.13.

Company-level read

Ticker impact

$BTMNeutralMedium confidence
Context

The news pertains directly to Bitcoin Depot's stock, which is highly relevant for trading decisions.

Expected impact

Potential short-term increase in stock price due to reverse split; long-term impact uncertain and depends on company performance.

Evidence & confidence

Reverse splits often lead to a temporary boost in share price, but do not alter fundamental valuation. The neutral sentiment and analyst hold rating indicate limited immediate upside.

Market effects

The cryptocurrency kiosk and blockchain-related sectors may experience minimal impact, as the news is company-specific.

Limited regional impact; primarily affects NASDAQ-listed stocks.

Negligible; the event is specific to a single company's corporate action.

Counterpoint

Some investors may interpret the reverse split as a sign of underlying financial distress or low stock price, which could be a bearish indicator.

Key entities

  • Bitcoin Depot

    A provider of cryptocurrency kiosks and related services.

Related articles

$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

$BHVNMed

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.